Recce Pharmaceuticals Selects CMAX for phase I/II UTI clinical trial
- Recce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility for a clinical trial to treat urinary tract infections (UTIs)
- The phase one and two intravenous clinical trial will assess RCE’s lead drug candidate, R327, in UTIs, with dosing to commence this quarter
- Recce will collect plasma and urine from 12 healthy males and females following dosing to evaluate R327’s concentrations and antibacterial effect in the urine on bacteria
- It follows an independent in-vitro study that found R327 had a fast effect against E. coli bacteria, which is responsible for around 90 per cent of UTIs
- Recce shares are trading at 58 cents at midday AEDT
